Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MCT 101

Drug Profile

MCT 101

Alternative Names: MCT-101

Latest Information Update: 26 Apr 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Minnesota
  • Developer Finch Therapeutics Group; University of Minnesota
  • Class Anti-inflammatories; Antineoplastics; Bacteria; Behavioural disorder therapies; Probiotics
  • Mechanism of Action Bacteria replacements; Microbiome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Non-small cell lung cancer; Pervasive child development disorders

Most Recent Events

  • 22 Nov 2022 Phase-II clinical trials in Non-small cell lung cancer (First-line therapy, Metastatic disease, Late-stage disease; Combination therapy) in USA (PO) (NCT04105270)
  • 28 Jan 2022 Finch Therapeutics in-licenses formulations comprising human fecal microbes, methods of increasing microbiota diversity, and methods of decreasing the relative abundance of certain bacteria from University of Minnesota
  • 15 Nov 2019 Phase-II clinical trials in Pervasive child development disorders (In children, In adolescents) in USA (PO) (NCT04182633)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top